Patents by Inventor Wilfried Rautenberg

Wilfried Rautenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chromenone derivatives
    Patent number: 8304416
    Abstract: Novel compounds of the formula I in which R1, R2, R3 and Het are as defined herein, which are inhibitors of tyrosine kinases and/or Raf kinases and can be employed for the treatment of tumors, for neuroprotection and for protection of the stress proteins of the skin.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: November 6, 2012
    Assignee: Merck Patent GmbH
    Inventors: Teresa Mujica-Fernaud, Herwig Buchholz, Wilfried Rautenberg, Christian Sirrenberg
  • 1,3-BENZOXAZOLYL DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20120220611
    Abstract: Compounds of the formula I, the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases that are caused, mediated and/or propagated by angiogenesis. Compounds of the formula I are effective inhibitors of tyrosine kinases, in particular TIE-2 and VEGFR, and of Raf kinases.
    Type: Application
    Filed: May 8, 2012
    Publication date: August 30, 2012
    Applicant: MERCK PATENT GMBH
    Inventors: Wolfgang STÄHLE, Alfred JONCZYK, Wilfried RAUTENBERG
  • 1,3-benzoxazolyl derivatives as kinase inhibitors
    Patent number: 8242128
    Abstract: The invention relates to compounds of formula 1, the production and use thereof as a medicament for the treatment of diseases, particularly tumours and/or diseases caused, mediated or propagated by angiogenesis. The compounds of formula 1 are effective inhibitors of tyrosin kinases, particularly TIE-2 and VEGFR, and Raf-kinases.
    Type: Grant
    Filed: September 1, 2004
    Date of Patent: August 14, 2012
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Stähle, Alfred Jonczyk, Wilfried Rautenberg
  • N,N?-diphenylurea derivatives which are suitable as kinase inhibitors
    Patent number: 8097727
    Abstract: Compounds of the formula (I), in which R1a-R1e, R2a, R2b, R3 and R5 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: October 4, 2005
    Date of Patent: January 17, 2012
    Assignee: Merck patent GmbH
    Inventors: Wolfgang Staehle, Guenter Hoelzemann, Wilfried Rautenberg
  • Heterocyclic substituted bisarylurea derivatives
    Patent number: 8003657
    Abstract: The present invention relates to heterocyclic substituted bisarylurea derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Grant
    Filed: October 6, 2005
    Date of Patent: August 23, 2011
    Assignee: Merck Patent GmbH
    Inventors: Frank Stieber, Alfred Jonczyk, Guenter Hoelzemann, Hans-Peter Buchstaller, Lars Thore Burgdorf, Wilfried Rautenberg, Hartmut Greiner
  • CHROMENONE DERIVATIVES
    Publication number: 20110136830
    Abstract: Novel compounds of the formula I in which R1, R2, R3 and Het are as defined herein, which are inhibitors of tyrosine kinases and/or Raf kinases and can be employed for the treatment of tumours, for neuroprotection and for protection of the stress proteins of the skin.
    Type: Application
    Filed: February 15, 2011
    Publication date: June 9, 2011
    Inventors: Teresa MUJICA-FERNAUD, Herwig Buchholz, Wilfried Rautenberg, Christian Sirrenberg
  • N,N?-diphenylurea derivatives suitable as kinase inhibitors
    Patent number: 7846927
    Abstract: Compounds of the formula (I), in which R1, R3 and X have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: December 7, 2010
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Helene Crassier, Alfred Jonczyk, Wilfried Rautenberg
  • Amine derivatives
    Patent number: 7816365
    Abstract: Disclosed are compounds of formula (I), which are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and which can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: November 5, 2004
    Date of Patent: October 19, 2010
    Assignee: Merck Patent GmbH
    Inventors: Kai Schiemann, Guenter Hoelzemann, Wilfried Rautenberg
  • 2-oxadiazolechromone derivatives
    Patent number: 7772265
    Abstract: Novel compounds of the formula I in which R, X and n are as defined herein, are inhibitors of tyrosine kinase and can be employed for the treatment of tumours, for neuroprotection and for protection of the stress proteins of the skin.
    Type: Grant
    Filed: April 1, 2008
    Date of Patent: August 10, 2010
    Assignee: Merck Patent GmbH
    Inventors: Teresa Mujica-Fernaud, Herwig Buchholz, Christophe Carola, Wilfried Rautenberg, Christian Sirrenberg
  • Pyrazole derivatives
    Patent number: 7767696
    Abstract: Compounds of the formula (I), in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases, and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: March 8, 2006
    Date of Patent: August 3, 2010
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Helene Crassier, Wilfried Rautenberg
  • 4-Amino-5-oxo-8-phenyl-5H-pyrido(2,3-D) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours
    Patent number: 7745434
    Abstract: Compounds of the formula (I), in which R6, R7, R8, R9, Het1, X and X? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: June 29, 2010
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Karl-August Ackermann, Helene Crassier, Alfred Jonczyk, Wilfried Rautenberg, Gema Tarrason, Elisabet Rosell-Vives, Jaume Adan, Claudia Cases
  • Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases
    Patent number: 7696224
    Abstract: Compounds of the formula (I), in which R1a—R1e, R2a, R2b, R3 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: April 13, 2010
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Staehle, Guenter Hoelzemann, Wilfried Rautenberg
  • Pyrazole derivatives having tyrosine kinase inhibitory activity
    Patent number: 7662827
    Abstract: Compounds of the formula (I), in which R, X, R1, R2, R3 and R4 have the meanings indicated in Claim (1), are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: February 16, 2010
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Helene Crassier, Wilfried Rautenberg
  • HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES
    Publication number: 20090215799
    Abstract: The present invention relates to heterocyclic substituted bisarylurea derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Application
    Filed: October 6, 2005
    Publication date: August 27, 2009
    Inventors: Frank Stieber, Alfred Jonczyk, Guenter Hoelzemann, Hans-Peter Buchstaller, Lars Thore Burgdorf, Wilfried Rautenberg, Hartmut Greiner
  • Pyridopyrimidinones
    Patent number: 7547695
    Abstract: The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X? have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumors.
    Type: Grant
    Filed: October 14, 2004
    Date of Patent: June 16, 2009
    Assignee: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Helene Crassier, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Soler Riera
  • N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES
    Publication number: 20090124633
    Abstract: The present invention relates to heterocyclic substituted N-Oxides of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Application
    Filed: March 26, 2007
    Publication date: May 14, 2009
    Inventors: Alfred Jonczyk, Wilfried Rautenberg
  • Sulfonamides
    Patent number: 7528139
    Abstract: Compounds of the formula (I), in which R6, R7, R8, R9 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: March 17, 2005
    Date of Patent: May 5, 2009
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Guenter Hoelzemann, Helene Crassier, Alfred Jonczyk, Wolfgang Staehle, Wilfried Rautenberg
  • BENZIMIDAZOLES
    Publication number: 20090082404
    Abstract: Novel compounds of the formula I in which R1, R1?, L, E, G, M, Q, U, R2, m, p and q have the meanings indicated in Claim 1 and are, for example, inhibitors of tyrosine kinases, for example TIE-2, and can be employed, for example, for the treatment of tumours or other diseases.
    Type: Application
    Filed: December 4, 2008
    Publication date: March 26, 2009
    Applicant: MERCK PATENT GMBH
    Inventors: Wolfgang STAEHLE, Hans-Peter Buchstaller, Alfred Jonczyk, Wilfried Rautenberg
  • Benzimidazoles
    Patent number: 7470702
    Abstract: Novel compounds of the formula I in which R1, R1?, L, E, G, M, Q, U, R2, m, p and q have the meanings indicated. Further, the compounds of formula I can be used as, for example, inhibitors of tyrosine kinases, for example TIE-2 , and can be employed, for example, for the treatment of tumours or other diseases.
    Type: Grant
    Filed: October 14, 2004
    Date of Patent: December 30, 2008
    Assignee: Merck Patent GmbH
    Inventors: Wolfgang Staehle, Hans-Peter Buchstaller, Alfred Jonczyk, Wilfried Rautenberg
  • Purine Derivatives as Inhibitors of Receptor Tyrosine Kinase Activity
    Publication number: 20080214582
    Abstract: Compounds of the formula (I), in which R1, R2, R3, R4 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: March 15, 2006
    Publication date: September 4, 2008
    Inventors: Guenter Hoelzemann, Helene Crassier, Wilfried Rautenberg, Alfred Jonczyk